Altimmune (ALT) Common Equity: 2010-2025
Historic Common Equity for Altimmune (ALT) over the last 15 years, with Sep 2025 value amounting to $185.6 million.
- Altimmune's Common Equity rose 39.16% to $185.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.6 million, marking a year-over-year increase of 39.16%. This contributed to the annual value of $123.5 million for FY2024, which is 36.37% down from last year.
- Latest data reveals that Altimmune reported Common Equity of $185.6 million as of Q3 2025, which was up 15.02% from $161.4 million recorded in Q2 2025.
- Altimmune's 5-year Common Equity high stood at $246.4 million for Q1 2021, and its period low was $123.5 million during Q4 2024.
- For the 3-year period, Altimmune's Common Equity averaged around $159.2 million, with its median value being $161.4 million (2025).
- Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 488.20% in 2021, then crashed by 36.37% in 2024.
- Quarterly analysis of 5 years shows Altimmune's Common Equity stood at $199.1 million in 2021, then decreased by 6.95% to $185.3 million in 2022, then rose by 4.75% to $194.1 million in 2023, then tumbled by 36.37% to $123.5 million in 2024, then spiked by 39.16% to $185.6 million in 2025.
- Its last three reported values are $185.6 million in Q3 2025, $161.4 million for Q2 2025, and $142.2 million during Q1 2025.